- Home
- CNTA vs LQDA Comparison
CNTA vs LQDA Comparison
Compare CNTA & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- LQDA
- Stock Information
- Founded
- CNTA 2020
- LQDA 2004
- Country
- CNTA United Kingdom
- LQDA United States
- Employees
- CNTA N/A
- LQDA N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- LQDA Health Care
- Exchange
- CNTA Nasdaq
- LQDA Nasdaq
- Market Cap
- CNTA 2.3B
- LQDA 2.5B
- IPO Year
- CNTA 2021
- LQDA 2018
- Fundamental
- Price
- CNTA $21.81
- LQDA $25.99
- Analyst Decision
- CNTA Strong Buy
- LQDA Strong Buy
- Analyst Count
- CNTA 11
- LQDA 9
- Target Price
- CNTA $30.60
- LQDA $32.11
- AVG Volume (30 Days)
- CNTA 1.5M
- LQDA 2.3M
- Earning Date
- CNTA 11-11-2025
- LQDA 11-12-2025
- Dividend Yield
- CNTA N/A
- LQDA N/A
- EPS Growth
- CNTA N/A
- LQDA N/A
- EPS
- CNTA N/A
- LQDA N/A
- Revenue
- CNTA $15,000,000.00
- LQDA $19,322,000.00
- Revenue This Year
- CNTA N/A
- LQDA $362.31
- Revenue Next Year
- CNTA N/A
- LQDA $418.29
- P/E Ratio
- CNTA N/A
- LQDA N/A
- Revenue Growth
- CNTA 118.88
- LQDA 30.20
- 52 Week Low
- CNTA $9.60
- LQDA $9.68
- 52 Week High
- CNTA $23.24
- LQDA $29.94
- Technical
- Relative Strength Index (RSI)
- CNTA 71.02
- LQDA 51.91
- Support Level
- CNTA $15.01
- LQDA $27.15
- Resistance Level
- CNTA $23.24
- LQDA $29.43
- Average True Range (ATR)
- CNTA 1.23
- LQDA 1.24
- MACD
- CNTA 0.59
- LQDA -0.58
- Stochastic Oscillator
- CNTA 82.62
- LQDA 8.25
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.